✦ LIBER ✦

Beyond immunosuppression - challenges in the clinical management of lupus nephritis

✍ Scribed by Masood, S; Jayne, D; Karim, Y

Book ID: 126290413
Publisher: SAGE Publications
Year: 2009
Tongue: English
Weight: 149 KB
Volume: 18
Category: Article
ISSN: 0961-2033
DOI: 10.1177/0961203308095330

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ten Common Mistakes in the Management of

Ten Common Mistakes in the Management of Lupus Nephritis

✍ Bose, Bhadran; Silverman, Earl D.; Bargman, Joanne M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 288 KB

P79 Systematic review and meta-analysis

P79 Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis.

✍ Vikas Majithia; Joshua T Swan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Immunosuppressive therapy in lupus nephr

Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

✍ Frédéric A. Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

Practical management of lupus nephritis

Practical management of lupus nephritis in pregnancy and the puerperium

✍ Karim, M Yousuf; D’Cruz, David P 📂 Article 📅 2010 🏛 Expert Reviews 🌐 English ⚖ 226 KB

Renal biopsy in the management of lupus

Renal biopsy in the management of lupus nephritis during pregnancy

✍ Chen, T. K.; Gelber, A. C.; Witter, F. R.; Petri, M.; Fine, D. M. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 129 KB

Early response to immunosuppressive ther

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

✍ Frédéric A. Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## Abstract ## Objective In the Euro‐Lupus Nephritis Trial (ELNT), 90 patients with lupus nephritis were randomly assigned to a high‐dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly pulses with escalating doses) or a low‐dose IV CYC regimen (6 pulses of 500 mg g